Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Dow
Merck
Johnson and Johnson
Express Scripts
Medtronic
Baxter

Last Updated: December 14, 2019

DrugPatentWatch Database Preview

Litigation Details for BRAINTREE LABORATORIES, INC. v. LUPIN ATLANTIS HOLDINGS SA (D.N.J. 2011)

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

BRAINTREE LABORATORIES, INC. v. LUPIN ATLANTIS HOLDINGS SA (D.N.J. 2011)

Docket   Start Trial Date Filed 2011-03-09
Court District Court, D. New Jersey Date Terminated 2015-06-04
Cause 35:145 Patent Infringement Assigned To Peter G. Sheridan
Jury Demand None Referred To Magistrate Judge Lois H. Goodm
Parties BRAINTREE LABORATORIES, INC.; NOVEL LABORATORIES, INC.
Patents 5,569,652; 5,616,346; 5,710,183; 9,018,352
Attorneys HILLEL IRA PARNESS; LEDA DUNN WETTRE; MICHAEL JAMES GESUALDO
Link to Docket External link to docket
Small Molecule Drugs cited in BRAINTREE LABORATORIES, INC. v. LUPIN ATLANTIS HOLDINGS SA
The small molecule drugs covered by the patents cited in this case are   Start Trial ,   Start Trial ,   Start Trial , and   Start Trial .
Biologic Drugs cited in BRAINTREE LABORATORIES, INC. v. LUPIN ATLANTIS HOLDINGS SA

The biologic drugs covered by the patents cited in this case are   Start Trial ,   Start Trial , and   Start Trial .

Details for BRAINTREE LABORATORIES, INC. v. LUPIN ATLANTIS HOLDINGS SA (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2013-06-04 380 Opinion (U.S. Patent No. 5,616,346 (1997)) (DTX 292) 1 ln 1997, Craig Aronchick was granted a patent for a tablet…Act alleging infringement of U.S. Patent No. 6,946,149 (‘149 Patent), a-pu,rgative that cleanses the colon… inventors of the ‘149 Patent. They assigned their interest in the ‘ 149 Patent to Braintree, § Novel…generic drug manufacturer. 2. The ‘149 Patent The ‘149 Patent is entitled Salt Solution for Colon Cleansing… No. 4,452,779 lk produced by ill patent relates tockenll patent discloses providing sulfate salts External link to document
2014-04-22 398 USCA Judgment(Use if Mandate will follow) Id. at 1319 (quoting U.S. Patent No. 5,569,652). But the FDA-approved NDA…District of New Jersey that U.S. Patent No. 6,946,149 (“’149 patent”) held by Braintree Laboratories…claimed in a patent or the use of which is claimed in a patent.’” Eli Lilly… claimed in a patent or the use of which is claimed in a patent. …asserted patent when the FDA- approved dose is not the dose claimed in the patent. As External link to document
2015-06-01 461 Memorandum in the 303 Study. Tr. at 325:4-17, 330:9-18, 352: 17-353: 1. Dr. Goldfarb was the…in a patent or the use of which is claimed in a patent before the expiration of such patent." …infringed Claims 15, 18, 19, 20, and 23 of the '149 patent. That reversal was based upon the Federal Circuit… in the general class of persons to whom the patent compositions are directed, i.e. a patient population…, 1247-48 (Fed. Cir. 1998). Application of a patent claim to an accused product is a fact-specific External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKesson
McKinsey
Johnson and Johnson
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.